These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 15775731)

  • 1. Insulin sensitivity in women with coronary heart disease during hormone replacement therapy.
    Os I; Os A; Abdelnoor M; Larsen A; Birkeland K; Westheim A
    J Womens Health (Larchmt); 2005 Mar; 14(2):137-45. PubMed ID: 15775731
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma leptin in postmenopausal women with coronary artery disease: effect of transdermal 17beta-estradiol and intermittent medroxyprogesterone acetate.
    Os I; Os A; Abdelnoor M; Larsen A; Birkeland K; Westheim A
    Climacteric; 2003 Sep; 6(3):204-10. PubMed ID: 14567768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hormone replacement therapy does not affect plasma homocysteine in postmenopausal women with coronary artery disease. Free tissue factor pathway inhibitor antigen, a circulating anticoagulant, is related to plasma homocysteine.
    Os I; Os A; Sandset PM; Bølling S; Seljeflot I; Djurovic S; Westheim A
    Cardiology; 2002; 98(1-2):6-12. PubMed ID: 12373040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum androgen levels and insulin resistance in postmenopausal women: association with hormone therapy, tibolone and raloxifene.
    Christodoulakos G; Lambrinoudaki I; Panoulis C; Sioulas V; Rizos D; Caramalis G; Botsis D; Creatsas G
    Maturitas; 2005 Apr; 50(4):321-30. PubMed ID: 15780533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of estrogen therapy on insulin resistance and plasminogen activator inhibitor type 1 concentrations in postmenopausal women.
    Saucedo R; Basurto L; Zarate A; Martínez C; Hernandez M; Galván R
    Gynecol Obstet Invest; 2007; 64(2):61-4. PubMed ID: 17264514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of hormonal replacement therapy on plasma sex hormone-binding globulin, androgen and insulin-like growth factor-1 levels in postmenopausal women.
    Stomati M; Hartmann B; Spinetti A; Mailand D; Rubino S; Albrecht A; Huber J; Petraglia F; Genazzani AR
    J Endocrinol Invest; 1996 Sep; 19(8):535-41. PubMed ID: 8905477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The EWA (estrogen in women with atherosclerosis) study: a randomized study of the use of hormone replacement therapy in women with angiographically verified coronary artery disease. Characteristics of the study population. Effects on lipids and lipoproteins.
    Os I; Hofstad AE; Brekke M; Abdelnoor M; Nesheim BI; Jacobsen AF; Birkeland K; Larsen A; Midtbo K; Westheim A
    J Intern Med; 2000 Apr; 247(4):433-41. PubMed ID: 10792556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of continuous combined estradiol-norethisterone acetate preparations on insulin sensitivity in postmenopausal nondiabetic women.
    Kimmerle R; Heinemann L; Heise T; Bender R; Weyer C; Hirschberger S; Berger M
    Menopause; 1999; 6(1):36-42. PubMed ID: 10100178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and tolerability of continuous combined hormone replacement therapy in early postmenopausal women.
    Mattsson LA; Skouby S; Rees M; Heikkinen J; Kudela M; Stadnicki-Kolendo A; Mattila L; Salminen K; Vuorela A; Mustonen M;
    Menopause Int; 2007 Sep; 13(3):124-31. PubMed ID: 17785038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of hormone replacement therapy on insulin secretion and insulin sensitivity in postmenopausal diabetic women.
    Borissova AM; Tankova T; Kamenova P; Dakovska L; Kovacheva R; Kirilov G; Genov N; Milcheva B; Koev D
    Gynecol Endocrinol; 2002 Feb; 16(1):67-74. PubMed ID: 11915585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glycaemic control and hormone replacement therapy: implications of the Postmenopausal Estrogen/Progestogen Intervention (PEPI) study.
    Fineberg SE
    Drugs Aging; 2000 Dec; 17(6):453-61. PubMed ID: 11200306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of transdermal and oral estrogen replacement on lipids and glucose metabolism in postmenopausal women with type 2 diabetes mellitus.
    Araújo DA; Farias ML; Andrade AT
    Climacteric; 2002 Sep; 5(3):286-92. PubMed ID: 12419087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transdermal estradiol and lipid profile: effects on a specific group of Brazilian postmenopausal women.
    Callejon DR; Rios DR; Franceschini SA; Toloi MR
    Arq Bras Cardiol; 2009 Dec; 93(6):571-5, 617-22. PubMed ID: 20379635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The somatotropic axis in postmenopausal women during six month of transdermal continuous 17beta-estradiol administration combined with oral medroxyprogesterone.
    Milewicz T; Krzysiek J; Rogatko I; Sztefko K; Stochmal E; Hubalewska-Dydejczyk A; Jach R; Radowicki S
    Ginekol Pol; 2011 Apr; 82(4):254-8. PubMed ID: 21721462
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A 10-year follow-up of postmenopausal women on long-term continuous combined hormone replacement therapy: Update of safety and quality-of-life findings.
    Heikkinen J; Vaheri R; Timonen U
    J Br Menopause Soc; 2006 Sep; 12(3):115-25. PubMed ID: 16953985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of compounded bioidentical transdermal hormone therapy on hemostatic, inflammatory, immune factors; cardiovascular biomarkers; quality-of-life measures; and health outcomes in perimenopausal and postmenopausal women.
    Stephenson K; Neuenschwander PF; Kurdowska AK
    Int J Pharm Compd; 2013; 17(1):74-85. PubMed ID: 23627249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Continuous combined hormone replacement therapy relieves climacteric symptoms and improves health-related quality of life in early postmenopausal women.
    Pitkin J; Smetnik VP; Vadász P; Mustonen M; Salminen K; Ylikangas S;
    Menopause Int; 2007 Sep; 13(3):116-23. PubMed ID: 17785037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conjugated estrogen/progestagen versus tibolone hormone replacement therapy in postmenopausal women: Effects on carbohydrate metabolism and serum sex hormone-binding globulin.
    Odmark IS; Carlström K; Jonsson B; Jonasson AF
    Maturitas; 2006 Jan; 53(1):89-96. PubMed ID: 15964160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of continuation of postmenopausal hormone replacement therapy: transdermal versus oral estrogen.
    Ettinger B; Pressman A; Bradley C
    Menopause; 1998; 5(3):152-6. PubMed ID: 9774760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Continuation of postmenopausal hormone replacement therapy in a large health maintenance organization: transdermal matrix patch versus oral estrogen therapy.
    Ettinger B; Pressman A
    Am J Manag Care; 1999 Jun; 5(6):779-85. PubMed ID: 10538456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.